Trials / Completed
CompletedNCT02797015
Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS
A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn about the pharmacokinetics and pharmacodynamics of RPC1063 in RMS.
Detailed description
The purpose of this study is to characterize the full pharmacokinetic and pharmacodynamics profiles of RPC1063 in patients with relapsing multiple sclerosis (RMS) following multiple-dose administration of the two different dosing regimens that are being evaluated in the Phase 3 RMS studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RPC1063 | Oral capsule daily |
Timeline
- Start date
- 2016-06-23
- Primary completion
- 2017-10-20
- Completion
- 2017-10-20
- First posted
- 2016-06-13
- Last updated
- 2018-03-27
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02797015. Inclusion in this directory is not an endorsement.